BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28

• Pharm Country

  Bristol-Myers Squibb Company to Present Data on 13 Oncology Compounds During 2010 American Society of Clinical Oncology Annual Meeting

  May 21, 2010

   · 

  1 min read
• Biotech Beach

  Study Finds Masimo Corporation PVI Beneficial in Identifying Patients At-Risk for Developing Anesthesia-Induced Hypotension

  May 21, 2010

   · 

  6 min read
• Pharm Country

  NPS Pharmaceuticals, Inc. to Present at Citi Global Health Care Conference

  May 21, 2010

   · 

  1 min read
• Deals

  EPIX Pharmaceuticals, Inc. Announces a Change in the May 28, 2010 Auction Sale of Imaging Agents to June 22, 2010

  May 21, 2010

   · 

  1 min read
• GTX Corp Announces Upcoming American Society of Clinical Oncology Presentations of Additional Study Results from Clinical Trials Evaluating Ostarine(TM) for Cancer Cachexia and Toremifene 80 mg for the Reduction of Fractures in Men with Prostate Cancer on

  May 21, 2010

   · 

  1 min read
• BioMidwest

  Invacare Corporation Declares Quarterly Dividend

  May 21, 2010

   · 

  1 min read
• Genetown

  Echo Therapeutics Needle-Free Symphony(TM) tCGM System and Prelude(TM) SkinPrep System Featured in LifeTech Capital Audio Interview

  May 21, 2010

   · 

  5 min read
• Drug Development

  Report on Phase II Clinical Study of Marshall Edwards, Inc.'s Phenoxodiol in Prostate Cancer to Be Presented at American Society of Clinical Oncology

  May 21, 2010

   · 

  4 min read
• Drug Development

  ZIOPHARM Oncology, Inc. to Present Further Palifosfamide PICASSO Phase II Results in Oral Session at American Society of Clinical Oncology

  May 21, 2010

   · 

  1 min read
• Deals

  Ligand Pharmaceuticals Inc. Acquired Milestone and Royalty Interest in AstraZeneca PLC IL-9 Program for Asthma For $2.75 Million

  May 21, 2010

   · 

  4 min read